{"id":"hydromorphone-hci-oros","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Nausea"},{"rate":"5-10%","effect":"Vomiting"},{"rate":"5-10%","effect":"Constipation"},{"rate":"5-10%","effect":"Dizziness"},{"rate":"5-10%","effect":"Somnolence"}]},"_chembl":{"chemblId":"CHEMBL1237055","moleculeType":"Small molecule","molecularWeight":"321.80"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Hydromorphone acts as a potent agonist at the μ-opioid receptor, producing analgesia and euphoria.","oneSentence":"μ-opioid receptor agonist","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T04:02:05.299Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Moderate to severe pain"}]},"trialDetails":[{"nctId":"NCT00410878","phase":"PHASE1","title":"A Repeated Dose Study of the Metabolism and Action Evaluation of OROS Hydromorphone HCI (Slow Release) Tablets in Patients With Chronic Pain","status":"COMPLETED","sponsor":"Alza Corporation, DE, USA","startDate":"","conditions":"Pain, Analgesics, Opioid","enrollment":22},{"nctId":"NCT01532895","phase":"","title":"Clinical Usefulness and Quality of Life of OROS Hydromorphone in Patients Who Have Not Been Treated With a Strong Opioid","status":"COMPLETED","sponsor":"Janssen Korea, Ltd., Korea","startDate":"2011-09","conditions":"Pain","enrollment":400},{"nctId":"NCT00411164","phase":"PHASE3","title":"A Study to Evaluate the Effectiveness and Safety of Slow Release Hydromorphone HCL for Treatment of Patients With Osteoarthritis","status":"COMPLETED","sponsor":"Alza Corporation, DE, USA","startDate":"2003-11","conditions":"Osteoarthritis, Hip, Osteoarthritis, Knee","enrollment":990},{"nctId":"NCT00411034","phase":"PHASE3","title":"A Repeated-Dose Evaluation of Use of a Pain Relieving Drug and Safety of OROS Hydromorphone HCI in Patients With Chronic Cancer Pain","status":"COMPLETED","sponsor":"Alza Corporation, DE, USA","startDate":"","conditions":"Analgesics, Opioid, Pain","enrollment":463},{"nctId":"NCT00399295","phase":"PHASE1","title":"An Open-Label Evaluation of the Independent Effects of Coadministration of a High-Fat Meal and Naltrexone Blockade on the Pharmacokinetic Profile of Dilaudid OROS (Hydromorphone HCI) 16mg","status":"COMPLETED","sponsor":"Alza Corporation, DE, USA","startDate":"","conditions":"Analgesia","enrollment":30},{"nctId":"NCT00410787","phase":"PHASE3","title":"Safety and Tolerability of Long-term Administration of OROS Hydromorphone HCI (Slow Release) in Cancer Pain","status":"COMPLETED","sponsor":"Alza Corporation, DE, USA","startDate":"","conditions":"Analgesics, Opioid, Pain","enrollment":68},{"nctId":"NCT00399048","phase":"PHASE3","title":"An Effectiveness, Safety and Quality of Life Measures With Hydromorphone HCL, Dilaudid CR (Controlled Release)","status":"COMPLETED","sponsor":"Alza Corporation, DE, USA","startDate":"","conditions":"Osteoarthritis, Knee, Osteoarthritis, Hip","enrollment":140},{"nctId":"NCT00398788","phase":"PHASE2","title":"A Study on Efficacy (Effectiveness), Safety, and Impact on Quality of Life Measures of Dilaudid CR (Controlled Release);, Hydromorphone HCl in Patients With Chronic Low Back Pain","status":"COMPLETED","sponsor":"Alza Corporation, DE, USA","startDate":"","conditions":"Low Back Pain","enrollment":207},{"nctId":"NCT00410748","phase":"PHASE3","title":"Safety and Tolerability of Long-Term Administration of Hydromorphone HCI CR (Controlled Release)","status":"COMPLETED","sponsor":"Alza Corporation, DE, USA","startDate":"","conditions":"Pain, Analgesics, Opioid","enrollment":388},{"nctId":"NCT00411268","phase":"PHASE3","title":"Safety, Effectiveness, and Impact on Quality of Life on Long-Term Administration of OROS Hydromorphone Slow-Release in Patients With Chronic Low Back Pain","status":"COMPLETED","sponsor":"Alza Corporation, DE, USA","startDate":"","conditions":"Low Back Pain","enrollment":207},{"nctId":"NCT00410644","phase":"PHASE3","title":"A Repeated-Dose Evaluation of a Pain Relieving Drug Use and Safety of OROS Hydromorphone HCI in Patients With Chronic Non-Malignant Pain","status":"COMPLETED","sponsor":"Alza Corporation, DE, USA","startDate":"","conditions":"Pain, Analgesics, Opioid","enrollment":463},{"nctId":"NCT00410943","phase":"PHASE3","title":"Study of the Effectiveness and Tolerability of OROS Hydromorphone HCI SR(Slow-release) Tablets and Immediate-Release Hydromorphone Tablets in Patients With Chronic Pain","status":"COMPLETED","sponsor":"Alza Corporation, DE, USA","startDate":"","conditions":"Pain","enrollment":169},{"nctId":"NCT00411307","phase":"PHASE2","title":"A Randomized, Open-Label, Single-Dose, Small Study to Evaluate the Safety and Effectiveness of Hydromorphone in Patients With Short Term, Moderate to Severe Postoperative Pain","status":"COMPLETED","sponsor":"Alza Corporation, DE, USA","startDate":"","conditions":"Pain, Postoperative, Orthopedic Procedures, Analgesia","enrollment":50}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"Hydromorphone HCI OROS","genericName":"Hydromorphone HCI OROS","companyName":"Janssen Korea, Ltd., Korea","companyId":"janssen-korea-ltd-korea","modality":"Small molecule","firstApprovalDate":"","aiSummary":"μ-opioid receptor agonist Used for Moderate to severe pain.","enrichmentLevel":3,"visitCount":2,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}